Antipsychotic medication for challenging behaviour in people with intellectual disability: a systematic review of randomized controlled trials.

The authors hunted for every randomized trial that tested antipsychotic drugs on adults with intellectual disability and challenging behavior. They found only three trials. None gave clear proof that the drugs helped or hurt.

Because the evidence was so thin, they could not say yes or no to using these medicines for behavior control.

There is no solid evidence from RCTs that antipsychotics reduce challenging behavior in adults with ID. The three existing trials were too small or poorly done to guide practice.

In short, we are flying blind when we prescribe these drugs for behavior.

Burack et al. (2004) extends this worry. Their survey showed that, even after the 1999 "no evidence" verdict, nearly 900 Australians with ID were still on antipsychotics for behavior control. Practice raced ahead of science.

Cohen-Almeida et al. (2000) looked at side effects instead of benefits. They found that newer atypical antipsychotics caused fewer side effects than older drugs and about the same as no drug at all. This gives safety info but still no proof the drugs work.

Branford (1996) offers a small ray of hope for tapering. In a case series, some adults with ID could stop antipsychotics if they were on low doses and had mild behavior topographies. This suggests careful withdrawal is possible, even if efficacy is unproven.

If you serve adults with ID and challenging behavior, this paper is a red flag. Medications are often used without an evidence base. Start by auditing your caseload for antipsychotic polypharmacy. Pair any drug trial with tight data collection, and plan a taper when behavior stabilizes. Your ethical duty is to treat meds as an experiment, not a default.